MX2018012897A - Nuevos polipeptidos biespecificos contra cd137. - Google Patents

Nuevos polipeptidos biespecificos contra cd137.

Info

Publication number
MX2018012897A
MX2018012897A MX2018012897A MX2018012897A MX2018012897A MX 2018012897 A MX2018012897 A MX 2018012897A MX 2018012897 A MX2018012897 A MX 2018012897A MX 2018012897 A MX2018012897 A MX 2018012897A MX 2018012897 A MX2018012897 A MX 2018012897A
Authority
MX
Mexico
Prior art keywords
bispecific polypeptides
polypeptides against
novel bispecific
binding
designated
Prior art date
Application number
MX2018012897A
Other languages
English (en)
Inventor
Ellmark Peter
Furebring Christina
DAHLÉN Eva
Fritzell Sara
VEITONMÄKI Niina
NORLÉN Per
SÄLL Anna
Von Schantz Laura
Petersson Jessica
VARAS Laura
Original Assignee
Alligator Bioscience Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alligator Bioscience Ab filed Critical Alligator Bioscience Ab
Publication of MX2018012897A publication Critical patent/MX2018012897A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)

Abstract

La invención proporciona polipéptidos biespecíficos que comprenden un primer dominio de unión, designado B7, que es capaz de unirse específicamente a CD137, y un segundo dominio de unión, designado B2, que es capaz de unirse específicamente a un antígeno asociado a células tumorales. También se proporcionan composiciones farmacéuticas de tales polipéptidos biespecíficos y sus usos en medicina.
MX2018012897A 2016-04-22 2017-04-24 Nuevos polipeptidos biespecificos contra cd137. MX2018012897A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201607046 2016-04-22
PCT/EP2017/059656 WO2017182672A1 (en) 2016-04-22 2017-04-24 Novel bispecific polypeptides against cd137

Publications (1)

Publication Number Publication Date
MX2018012897A true MX2018012897A (es) 2019-01-17

Family

ID=58609424

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012897A MX2018012897A (es) 2016-04-22 2017-04-24 Nuevos polipeptidos biespecificos contra cd137.

Country Status (14)

Country Link
US (2) US20190169308A1 (es)
EP (1) EP3445788B1 (es)
JP (2) JP2019523630A (es)
KR (1) KR102426765B1 (es)
CN (1) CN109195994A (es)
AU (1) AU2017252233A1 (es)
BR (1) BR112018071612A2 (es)
CA (1) CA3021618A1 (es)
DK (1) DK3445788T3 (es)
ES (1) ES2910365T3 (es)
IL (1) IL262482A (es)
MX (1) MX2018012897A (es)
RU (1) RU2018139339A (es)
WO (1) WO2017182672A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201806972A (zh) 2016-05-27 2018-03-01 美商艾伯維生物醫療股份有限公司 雙特異性結合蛋白
TW201831513A (zh) 2016-06-20 2018-09-01 Ｆ星貝塔有限公司 結合物件(一)
ES2858091T3 (es) 2016-06-20 2021-09-29 F Star Therapeutics Ltd Moléculas de unión que se unen a PD-L1 y LAG-3
KR102632202B1 (ko) 2016-07-14 2024-02-02 젠맵 에이/에스 Cd40 및 cd137에 대한 다중특이적 항체
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
EA201990578A1 (ru) * 2016-09-23 2019-10-31 Связывающие молекулы, которые модулируют биологическую активность, проявляемую клеткой
CA3058477A1 (en) 2017-04-11 2018-10-18 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
KR102629972B1 (ko) 2017-04-13 2024-01-29 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
US11725060B2 (en) * 2017-07-20 2023-08-15 Aptevo Reserch and Development LLC Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods
CN118772242A (zh) 2017-08-04 2024-10-15 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
CA3071211A1 (en) 2017-08-04 2019-02-07 Genmab A/S Binding agents binding to pd-l1 and cd137 and use thereof
KR20200083574A (ko) * 2017-11-13 2020-07-08 크레센도 바이오로직스 리미티드 Cd137 및 psma에 결합하는 분자
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
WO2019121906A1 (en) 2017-12-19 2019-06-27 F-Star Beta Limited Specific pd-l1 binding sequences inserted in a ch3 domain
CN109970865B (zh) * 2017-12-28 2022-10-04 上海细胞治疗研究院 一种cd137双向激活共刺激分子受体及其用途
AU2019233523A1 (en) 2018-03-12 2020-10-01 Genmab A/S Antibodies
EP3774851A1 (en) * 2018-04-04 2021-02-17 BicycleTX Limited Heterotandem bicyclic peptide complexes
US20210198370A1 (en) * 2018-05-31 2021-07-01 Board Of Regents, The University Of Texas System Bi-specific antibodies and use thereof
EP3802601A1 (en) * 2018-06-06 2021-04-14 Leadartis, S.L. Trimeric polypeptide complexes and uses thereof
US11180531B2 (en) * 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
GB201811404D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811450D0 (en) * 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811415D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
KR20210076918A (ko) * 2018-10-10 2021-06-24 자임워크스 인코포레이티드 4-1bb 및 종양-관련 항원에 결합하는 항체 작제물 및 이의 용도
TW202021986A (zh) * 2018-10-11 2020-06-16 美商英伊布里克斯公司 5t4單域抗體及其治療性組合物
WO2020083277A1 (zh) * 2018-10-22 2020-04-30 上海一宸医药科技有限公司 一种双特异性抗体
KR20210099052A (ko) * 2018-11-30 2021-08-11 에이비엘바이오 주식회사 항-pd-l1/항-4-1bb 이중특이적 항체 및 이의 용도
WO2020127376A2 (en) * 2018-12-17 2020-06-25 Alligator Bioscience Ab Novel polypeptides
WO2020127374A2 (en) * 2018-12-17 2020-06-25 Alligator Bioscience Ab Novel polypeptides
TWI793395B (zh) * 2019-01-25 2023-02-21 大陸商信達生物製藥（蘇州）有限公司 結合ｐｄ-ｌ１和ｏｘ４０的雙特異性抗體
GB201905100D0 (en) * 2019-04-10 2019-05-22 Antibody Innovation Ltd Polypeptides and methods of use
EP3965827A1 (en) 2019-05-09 2022-03-16 BicycleTX Limited Bicyclic peptide ligands specific for ox40
BR112022001336A8 (pt) * 2019-07-26 2023-02-07 Abl Bio Inc Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo
EP4004053A4 (en) * 2019-07-26 2023-10-18 ABL Bio, Inc. BISPECIFIC ANTI-EGFR/ANTI-4-1BB ANTIBODIES AND USE THEREOF
TW202110485A (zh) 2019-07-30 2021-03-16 英商拜西可泰克斯有限公司 異質雙環肽複合物
CN112592404B (zh) * 2019-09-20 2023-07-25 上海交通大学医学院 抗体活性改造及其筛选方法
WO2021064428A1 (en) * 2019-10-03 2021-04-08 Bicycletx Limited Heterotandem bicyclic peptide complexes
EP3816185A1 (en) 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
WO2021101346A1 (en) * 2019-11-21 2021-05-27 Dong-A St Co., Ltd. Anti-ror1/anti-4-1bb bispecific antibodies and uses thereof
US20230048361A1 (en) 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells and uses of same
WO2021137231A1 (en) 2019-12-31 2021-07-08 Kahr Medical Ltd. Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
JP2023509516A (ja) 2020-01-07 2023-03-08 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム がん治療のための改良型ヒトメチルチオアデノシン／アデノシン枯渇酵素変種
JP2023516941A (ja) * 2020-02-28 2023-04-21 上海復宏漢霖生物技術股▲フン▼有限公司 抗ｃｄ１３７コンストラクト、多重特異性抗体及びその使用
EP4136122A4 (en) * 2020-04-15 2024-05-15 Zymeworks BC Inc. ANTIBODY CONSTRUCTS FOR BINDING 4-1BB AND FOLA RECEPTOR-ALPHA AND USES THEREOF
JP2023531042A (ja) * 2020-06-30 2023-07-20 諾納生物（蘇州）有限公司 ４－１ｂｂ結合タンパク質及びその用途
KR20230042524A (ko) * 2020-08-07 2023-03-28 주식회사 유틸렉스 항-her2 / 항-4-1bb 이중특이적 항체 및 이의 용도
CA3173151A1 (en) * 2020-11-03 2022-05-12 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies
CN116745309A (zh) * 2021-01-25 2023-09-12 柳韩洋行 用于纯化抗-4-1bb/抗-her2双特异性抗体的方法
EP4396235A2 (en) * 2021-09-02 2024-07-10 Memorial Sloan Kettering Cancer Center Anti-cd33 antibodies and uses thereof
EP4416183A1 (en) * 2021-10-12 2024-08-21 Concept to Medicine Biotech Co., Ltd. Single-domain 4-1bb antibodies
WO2023174521A1 (en) * 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
WO2024051752A1 (en) * 2022-09-06 2024-03-14 I-Mab Biopharma Co., Ltd. Multispecific constructs and uses thereof
WO2024061364A1 (zh) * 2022-09-22 2024-03-28 成都盛世君联生物技术有限公司 一种抗4-1bb纳米抗体及其制备和应用
WO2024085166A1 (ja) * 2022-10-19 2024-04-25 アステラス製薬株式会社 がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用
KR20240095012A (ko) * 2022-11-29 2024-06-25 (주) 테라베스트 Cd137 세포외 도메인을 포함하는 융합단백질, 이를 발현하는 면역세포 및 이의 용도
WO2024143643A1 (ko) * 2022-12-30 2024-07-04 앱클론(주) Cd137에 특이적으로 결합하는 어피바디 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
DE60040555D1 (de) * 1999-11-18 2008-11-27 Oxford Biomedica Ltd Küle
BR0108001A (pt) * 2000-02-01 2004-01-06 Tanox Inc Moléculas ativadoras de apc com ligação para cd-40
TW200616662A (en) 2004-09-10 2006-06-01 Wyeth Corp Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
EP2663580B1 (en) * 2011-01-10 2016-12-07 CT Atlantic Ltd. Combination therapy including tumor associated antigen binding antibodies
ES2692268T3 (es) 2011-03-29 2018-12-03 Roche Glycart Ag Variantes de Fc de anticuerpo
MX2014003313A (es) * 2011-09-23 2014-07-09 Amgen Res Munich Gmbh Moleculas de union biespecificas para 5t4 y cd3.
WO2014116846A2 (en) * 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
JP6629187B2 (ja) * 2014-04-07 2020-01-15 中外製薬株式会社 免疫活性化抗原結合分子
US20150307620A1 (en) * 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
CN105233291A (zh) * 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
EP3623386B1 (en) * 2015-01-08 2022-04-13 BioNTech SE Agonistic tnf receptor binding agents
JP2018503399A (ja) * 2015-01-14 2018-02-08 コンパス セラピューティクス リミテッド ライアビリティ カンパニー 多特異性免疫調節抗原結合構築物
US11008396B2 (en) * 2015-05-21 2021-05-18 Alligator Bioscience Ab Polypeptides
BR112019017628A2 (pt) * 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição

Also Published As

Publication number Publication date
KR20180135454A (ko) 2018-12-20
ES2910365T3 (es) 2022-05-12
CA3021618A1 (en) 2017-10-26
JP2022058338A (ja) 2022-04-12
EP3445788B1 (en) 2022-01-19
US20220213213A1 (en) 2022-07-07
CN109195994A (zh) 2019-01-11
BR112018071612A2 (pt) 2019-02-19
DK3445788T3 (en) 2022-04-11
US20190169308A1 (en) 2019-06-06
JP2019523630A (ja) 2019-08-29
RU2018139339A3 (es) 2020-09-28
EP3445788A1 (en) 2019-02-27
RU2018139339A (ru) 2020-05-22
KR102426765B1 (ko) 2022-07-29
IL262482A (en) 2018-12-31
WO2017182672A1 (en) 2017-10-26
AU2017252233A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
MX2018012897A (es) Nuevos polipeptidos biespecificos contra cd137.
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
MX2019009358A (es) Anticuerpo anti-gprc5d y molecula que comprende el anticuerpo.
PH12017502390A1 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
PH12017500803A1 (en) Anti-pd-1 antibodies
PH12017500190A1 (en) An anti-ctla4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition and use
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
MX2021002970A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor.
JOP20200312A1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
MX2019002968A (es) Un complejo novedoso que comprende un peptido penetrante de celulas, una carga y un agonista de peptido de tlr para tratamiento de cancer colorrectal.
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
MX2018003183A (es) Proteinas de enlace de antigeno biespecifico y tetraespecifico tetravalentes y usos de las mismas.
PH12016501760A1 (en) Anti-mcam antibodies and associated methods of use
TW201613980A (en) Anti-tissue factor monoclonal antibody
PH12018500254A1 (en) Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
MX2018008302A (es) Anticuerpo antigrupo de diferenciacion 9 (anti-cd9) terapeutico.
WO2020127376A3 (en) Polypeptides
MX2018009364A (es) Sal de succinato de citisina y uso de la misma.
AU2018279184A1 (en) Anti-TrkB antibodies
WO2020127374A3 (en) Polypeptides
WO2018062402A8 (en) CMET MONOCLONAL BINDING AGENTS, THEIR MEDICINAL CONJUGATES AND USES THEREOF
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.